Xiao Wang

Dr. Xiao Wang

Ningbo University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in AMB Express
Verified
Journal Article
Open access
PDF file
ZJZhou Jiale
Zhou Jiale
JJJiao Jian
Jiao Jian
TXTan Xinyi
Tan Xinyi
XHXie Haoji
Xie Haoji
HXHuang Xueqin
Huang Xueqin
Xiao WangXiao Wang
Xiao Wang
Methicillin-resistant staphylococcus aureus (MRSA) and its biofilm infection were considered as one of the main international health issues. There are still many challenges for treatment using traditional antibiotics. In this study, a mutant peptide of innate defense regulator (IDR-)1018 named 1018M was designed based on molecular docking and amino acid substitution technology. The antibacterial/biofilm activity and mechanisms against MRSA of 1018M were investigated for the first time. The minimum inhibitory concentration (MIC) of 1018M was reduced 1 time (MIC = 2 μg/mL) compared to IDR-1018. After treatment with 32 μg/mL 1018M for 24 h, the percentage of biofilm decreased by 78.9%, which was more effective than the parental peptide. The results of mechanisms exploration showed that 1018M was more potent than IDR-1018 at destructing bacterial cell wall, permeating cell membrane (20.4%–50.1% vs 1.45%–10.6%) and binding to stringent response signaling molecule ppGpp (increased 27.9%). Additionally, the peptides could also exert their activity by disrupting genomic DNA, regulating the expression of ppGpp metabolism and biofilm forming related genes (RSH, relP, relQ, rsbU, sigB, spA, codY, agrA and icaD). Moreover, the higher temperature, pH and pepsase stabilities provide 1018M better processing, storage and internal environmental tolerance. These data indicated that 1018M may be a potential candidate peptide for the treatment of MRSA and its biofilm infections.

3 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Xiao WangXiao Wang
Xiao Wang
HQHongda Qiu
Hongda Qiu
NYNa Yang
Na Yang
HXHaoji Xie
Haoji Xie
WLWeida Liang
Weida Liang
Hongze LiangHongze Liang
Hongze Liang

11 April 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HQHongda Qiu
Hongda Qiu
XZXing Zhao
Xing Zhao
YJYinli Jiang
Yinli Jiang
WLWeida Liang
Weida Liang
WWWeile Wang
Weile Wang
Hongze LiangHongze Liang
Hongze Liang

26 March 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
JZJingjing Zhao
Jingjing Zhao
DQDou Qian
Dou Qian
LZLuyang Zhang
Luyang Zhang
Xiao WangXiao Wang
Xiao Wang
JZJianfeng Zhang
Jianfeng Zhang
Epigallocatechin gallate (EGCG) has attracted increasing attention thanks to its multi-bioactivities, and people are keen on improving the antioxidative and antibacterial performance of EGCG. Based on the favorable biofunctionality of Zn2+ and chitosan (CS), an EGCG derivative with a novel formula, i.e., EGCG–Zn–CS, is presented in this study. The structure of EGCG–Zn–CS was characterized by FT-IR, UV-vis, TGA, XPS, and SEM–EDS. The radical elimination results indicate that 0.1 mg mL−1 of EGCG–Zn–CS demonstrates DPPH radical and hydroxyl radical scavenging activities of 94.8% and 92.3%, while 0.1 mg mL−1 of EGCG exhibits only 78.5% and 75.6%, respectively, which means improved antioxidative activity of EGCG–Zn–CS was obtained. Inhibitory experiments against Staphylococcus aureus and Escherichia coli reveal that the minimal inhibitory concentrations (MICs) of EGCG–Zn–CS were 15.625 μg mL−1 and 187.5 μg mL−1, whereas the minimal bactericide concentrations (MBCs) were 46.875 μg mL−1 and 750 μg mL−1, respectively, which indicate that EGCG–Zn–CS exerts much higher antibacterial activity than EGCG. It can be concluded that the complexing of zinc cations and CS could amazingly improve both the antioxidative and antibacterial activity of EGCG, and it is expected that an exploration of EGCG–Zn–CS may inspire the development of simultaneous effective antioxidant and antibacterial agents.

20 February 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
XTXinyi Tan
Xinyi Tan
HXHaoji Xie
Haoji Xie
Bin ZhangBin Zhang
Bin Zhang
JZJiale Zhou
Jiale Zhou
ZDZhende Dou
Zhende Dou
NWNing Wang
Ning Wang
Methicillin-resistant Staphylococcus aureus (MRSA) and its biofilms infection is still a serious threat to global health. It is urgent to develop efficient drugs by repositioning or designing drugs to solve this problem. In this study, the antibacterial/biofilm activity and mechanisms of ivermectin (D) and its 4″-position amino substitution derivative (D4) against MRSA were investigated. The minimum inhibitory concentration (MIC) of D was 20 μg/mL, which is four times higher than D4 (MIC = 5 μg/mL). The mechanism research demonstrated that D4 was more potent than D at destroying bacterial cell wall, permeating cell membrane (6.25–36.0% vs 1.92–6.04%) and binding to MRSA genomic DNA. Moreover, after incubation with 10–40 μg/mL D4 for 24 h, the percentages of biofilm decreased by 21.2–92.9%, which was more effective than D (no significant change at 40 μg/mL). The antibiofilm effect is achieved by regulating the expression of related genes (RSH, relQ, rsbU, sigB, spA, and icaD). Additionally, though the higher hemolysis makes D4 a safety risk for intravenous injection, other administration options could be considered as well. Therefore, all the results have indicated that D4 may be a potential candidate compound for the treatment of MRSA and its biofilm infections.

29 March 2024 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
QWQiang Wang
Qiang Wang
YYYuxin Yang
Yuxin Yang
XDXunxi Dong
Xunxi Dong
HWHao Wang
Hao Wang
LDLijian Ding
Lijian Ding
Xiao WangXiao Wang
Xiao Wang